# Patient-Trial Match Report

*Generated: 2026-01-05 18:28:37*

## Patient Profile

- **Age**: 52
- **Sex**: Female
- **Cancer Type**: NSCLC
- **Biomarkers**: EGFR exon 19 deletion

**Clinical Description**:
> 52-year-old Asian female with EGFR-mutant (exon 19 deletion) metastatic NSCLC. Initially treated with osimertinib with excellent response lasting 18 months. Now progressed with new bone metastases and enlarging lung primary. Liquid biopsy shows acquired C797S resistance mutation. No CNS involvement. Interested in combination trials or next-generation EGFR inhibitors. Never smoker, excellent functional status. No significant comorbidities. Labs: all WNL including LFTs.

- **Location Preference**: United States

## Search Summary

- **Search terms used**: 5
- **Total trials evaluated**: 60
- **Excluded by fast filter**: 11
- **LLM scored**: 49

## ðŸŸ¢ HIGH Likelihood (14 trials)

### [NCT03851445](https://clinicaltrials.gov/study/NCT03851445)

**LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)**

- **Sponsor**: SWOG Cancer Research Network
- **Phase**: Phase 2/Phase 3
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 52
- Sex: female
- Cancer type: NSCLC, confirmed by biomarker (EGFR exon 19 deletion)
- ECOG status: 0
- Prior therapies: osimertinib
- No brain metastases
- Country: United States

**? Uncertainties:**
- No information on adequate tumor tissue available
- No confirmation on ctDNA testing
- Exact treatment line for osimertinib treatment prior to progression needs further validation

**Assessment:**
> The patient's cancer type matches the trial's focus on NSCLC, and she has received prior systemic treatment (osimertinib) which is in line with the eligibility for previously treated patients. The patient meets other criteria like age and ECOG status, though there is some uncertainty regarding tumor tissue adequacy and ctDNA requirements.

---

### [NCT05394831](https://clinicaltrials.gov/study/NCT05394831)

**A Phase 1/2, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of JIN-A02 in Patients With EGFR Mutant Advanced Non-small Cell Lung Cancer**

- **Sponsor**: J Ints Bio
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 52
- ECOG status: 0
- Cancer type: NSCLC
- Biomarker: EGFR exon 19 deletion
- Prior therapies: osimertinib (previously treated)
- No brain metastases
- Co-mutation: EGFR C797S

**? Uncertainties:**
- Laboratory values (all WNL including LFTs not explicitly confirmed)
- Specific measurable lesion details not provided

**Assessment:**
> The patient's cancer type (NSCLC) matches the trial's condition of studying advanced EGFR mutant NSCLC. The patient has previously been treated with osimertinib, which aligns with the trial's requirement for patients who have shown disease progression after standard treatment. The presence of the C797S mutation also fits well with the inclusion criteria for the study. No major conflicts were found, supporting a high likelihood of eligibility.

---

### [NCT05498428](https://clinicaltrials.gov/study/NCT05498428)

**A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer**

- **Sponsor**: Janssen Research & Development, LLC
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has histologically confirmed metastatic non-small cell lung cancer (NSCLC).
- Patient has EGFR exon 19 deletion mutation, which is required for the trial.
- Patient has ECOG status of 0, which is acceptable.
- Patient has no brain metastases, which meets the criterion.

**? Uncertainties:**
- All organ function labs are stated as WNL but specific values are not provided.

**Assessment:**
> The patient has the appropriate cancer type (NSCLC) and confirmed biomarker (EGFR exon 19 deletion). The ECOG status is acceptable for enrollment. The only uncertainty relates to specific organ function lab values, but overall the patient condition and treatment line is compatible with the trial criteria.

---

### [NCT05519293](https://clinicaltrials.gov/study/NCT05519293)

**A Phase I/IIa, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Preliminary Anti-tumor Activity of H002 in Patients With Active EGFR Mutation Locally Advanced or Metastatic NSCLC**

- **Sponsor**: RedCloud Bio
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has a confirmed diagnosis of metastatic NSCLC.
- Patient has an EGFR exon 19 deletion, which is an active EGFR mutation associated with TKI sensitivity.
- Patient has documented disease progression on osimertinib, a third-generation EGFR-TKI.
- ECOG status is 0, which is acceptable for trial participation.
- Patient has no brain metastases.

**Assessment:**
> The patient has a diagnosis of metastatic non-small cell lung cancer (NSCLC) and an active EGFR mutation (exon 19 deletion). She has previously been treated with osimertinib and has documented disease progression, making her eligible for the previously treated patient category of this trial. All other relevant criteria are met.

---

### [NCT06667076](https://clinicaltrials.gov/study/NCT06667076)

**A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination With Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination With Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer**

- **Sponsor**: Janssen Research & Development, LLC
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Histologically confirmed advanced or metastatic non-small cell lung cancer (NSCLC)
- Epidermal growth factor resistance-mutation (EGFRm) with exon 19 deletion
- ECOG performance status of 0
- No brain metastases

**? Uncertainties:**
- Need verification of measurable lesions according to RECIST version (v)1.1
- Recovery status from prior therapy toxicities is not explicitly stated

**Assessment:**
> The patient's cancer type matches the trial as they have advanced NSCLC with the required EGFR mutation. The patient is previously treated but the trial allows previously treated patients in the second-line setting. The ECOG status is acceptable, and there are no brain metastases. Minor uncertainties exist regarding measurable lesions and recovery from prior therapy, but overall fit is strong.

---

### [NCT06907615](https://clinicaltrials.gov/study/NCT06907615)

**An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)**

- **Sponsor**: Shanghai Henlius Biotech
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has metastatic NSCLC, which matches the trial's cancer type.
- Patient has previously received osimertinib, fulfilling the requirement of prior standard treatment failure.
- ECOG status is 0, meeting the trial's requirement.
- No brain metastases, which aligns with the eligibility criteria.
- The patient is aged 52, which meets the age requirement of being â‰¥ 18.

**? Uncertainties:**
- Need for confirmation of adequate organ function, though labs are stated to be within normal limits.
- Confirmation of prior treatment specifics beyond osimertinib (e.g., any platinum-based chemotherapy) is not explicitly provided.

**Assessment:**
> The patient's cancer type is metastatic NSCLC, which matches the target indication of the trial. The patient has received prior treatment (osimertinib) and is interested in further options. Although there are some uncertainties regarding organ function and specific prior treatments, the major eligibility criteria are satisfactorily met.

---

### [NCT06659458](https://clinicaltrials.gov/study/NCT06659458)

**Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients**

- **Sponsor**: Our Lady of the Lake Hospital
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient is 52 years old.
- Patient is biologically born female.
- Patient is diagnosed with EGFR positive lung cancer (NSCLC, EGFR exon 19 deletion).
- Patient has an ECOG status of 0.

**Assessment:**
> The patient's cancer type (NSCLC with EGFR exon 19 deletion) matches the trial conditions, and the patient meets age and biological sex criteria. There are no conflicts or uncertainties regarding the provided eligibility criteria.

---

### [NCT04665206](https://clinicaltrials.gov/study/NCT04665206)

**Phase I/II, Multi-Center, Open-Label Study of VT3989, Alone or in Combination, in Patients With Locally Advanced or Metastatic Solid Tumors**

- **Sponsor**: Vivace Therapeutics, Inc
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has pathologically diagnosed metastatic NSCLC.
- Patient has exon 19 deletion, which is required for part of the trial.

**? Uncertainties:**
- Organ function labs are reported as WNL but not explicitly detailed.

**Assessment:**
> The patient's cancer type is NSCLC, which is an eligible condition for the trial. The patient has an exon 19 deletion, making her suitable for the combination cohort. She is also ECOG 0, meeting the performance status requirement. The only uncertainty is the explicit confirmation of organ functions, but overall, she meets the other critical eligibility criteria.

---

### [NCT04314401](https://clinicaltrials.gov/study/NCT04314401)

**Cancer Moonshot Biobank Research Protocol**

- **Sponsor**: National Cancer Institute (NCI)
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Cancer type is NSCLC, which matches the trial conditions studied
- Patient is currently progressing on a regimen of standard of care therapy
- Age is 52, which meets the minimum age requirement of 13
- ECOG status is 0, which is acceptable

**? Uncertainties:**
- No information provided on whether archival tissue is available
- No information on assessments of organ function labs

**Assessment:**
> The patient's cancer type is non-small cell lung cancer (NSCLC), which is eligible for the trial. The patient is previously treated with osimertinib and is currently progressing, fitting the treatment line requirements. All other core eligibility criteria are met, with only minor uncertainties regarding archival tissue and organ functions.

---

### [NCT05736029](https://clinicaltrials.gov/study/NCT05736029)

**PROPHETIC Extended - Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Extended Study.**

- **Sponsor**: OncoHost Ltd.
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 52
- Sex: female
- Cancer type: NSCLC
- ECOG status: 0

**Assessment:**
> The patient's cancer type (NSCLC) directly matches the trial's conditions. The patient is previously treated with osimertinib, which fits within the scope of the trial focusing on previously treated patients. The patient's age and ECOG score are within accepted limits, ensuring no conflicts with inclusion criteria.

---

### [NCT06131840](https://clinicaltrials.gov/study/NCT06131840)

**An Open-label Phase 1 Study to Investigate PF-08046050 (SGN-CEACAM5C) in Adults With Advanced Solid Tumors**

- **Sponsor**: Seagen, a wholly owned subsidiary of Pfizer
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Cancer type is NSCLC, which is included in the trial conditions studied.
- ECOG status is 0, which meets the eligibility criteria.

**? Uncertainties:**
- Patient's organ function labs are reported as WNL but specifics are not provided.

**Assessment:**
> The patient's cancer type of NSCLC matches the trial's conditions, and the ECOG status is acceptable. The only uncertainty is regarding specific organ function details, which do not necessarily disqualify the patient.

---

### [NCT07090499](https://clinicaltrials.gov/study/NCT07090499)

**A Phase 1 Open-label Study to Investigate PF-08046876 in Adult Participants With Advanced Solid Tumors.**

- **Sponsor**: Pfizer
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age is 52, which meets the age requirement of 18 years or older.
- ECOG status is 0, which is within the acceptable range of 0-1.
- The patient has advanced non-small cell lung cancer (NSCLC), which matches the trial's conditions studied.
- The patient has measurable disease as indicated by new bone metastases and enlarging lung primary.
- Patient has experienced progression following standard treatment with osimertinib.

**? Uncertainties:**
- Exact resolution status of acute effects of prior anticancer therapy is not explicitly stated.
- Details regarding the requirement for pre-treatment tumor tissue submission are unclear.

**Assessment:**
> The patient's cancer type matches the trial's indication for advanced NSCLC, and she has progressed after prior treatment, fitting into the previously treated category. The ECOG status and age are acceptable; however, there are some minor uncertainties about acute effects and tumor tissue submission.

---

### [NCT06706076](https://clinicaltrials.gov/study/NCT06706076)

**A Phase 1/2 Open-Label, Multicenter, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH-30643 in Adult Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (SOLARA)**

- **Sponsor**: BlossomHill Therapeutics
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 75%

**âœ“ Supporting Factors:**
- Patient has NSCLC, which matches the trial focus.
- Patient has an EGFR mutation (exon 19 deletion), qualifying for the trial's mutation criteria.
- Patient has an ECOG status of 0.
- Patient has received prior standard therapy (osimertinib), which fits the previous treatment requirement.

**? Uncertainties:**
- No specific information about the presence of measurable target extracranial lesions.
- No explicit mention of organ function lab values (all WNL).

**Assessment:**
> The patient's cancer type (NSCLC) and biomarker (EGFR exon 19 deletion) match the trial requirements, and the patient has prior treatment, which is acceptable for this phase of the study. The primary uncertainties involve the presence of measurable lesions and organ function lab values, but since other criteria are met, the patient likely qualifies.

---

### [NCT06562192](https://clinicaltrials.gov/study/NCT06562192)

**Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers**

- **Sponsor**: Novartis Pharmaceuticals
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 75%

**âœ“ Supporting Factors:**
- Age (52) is greater than 18 years old
- Cancer type (NSCLC) matches the trial conditions studied
- ECOG status (0) indicates excellent functional status
- No brain metastases present
- Prior therapies (osimertinib) align with treatment line criteria

**? Uncertainties:**
- Lesions showing 68Ga-NNS309 uptake (not provided in patient profile)
- Lab values for absolute neutrophil count, hemoglobin, platelet count, and creatinine clearance (not provided)

**Assessment:**
> The patient's cancer type (NSCLC) matches the trial criteria. The patient is 52 years old and has no brain metastases, while their ECOG status is 0. They have previously been treated with osimertinib, which aligns with the trial's inclusion criteria for patients who have actionable genomic alterations and have progressed following targeted therapy. However, there is uncertainty regarding the lesion uptake of 68Ga-NNS309 and missing organ function lab values.

---

## ðŸŸ¡ MEDIUM Likelihood (3 trials)

### [NCT06660407](https://clinicaltrials.gov/study/NCT06660407)

**Grid Radiotherapy for Advanced Non-Small Cell Lung Cancer at the Time of Progression on Immune Checkpoint Inhibition**

- **Sponsor**: Mayo Clinic
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 65%

**âœ“ Supporting Factors:**
- Age is 52 years (â‰¥ 18 years)
- ECOG status is 0
- Cancer type is NSCLC and is Stage IV
- No brain metastases, which is allowed
- No ongoing systemic treatment or steroids

**âœ— Potential Conflicts:**
- Currently progressing on osimertinib indicates the patient is not on standard of care first-line immunotherapy or chemoimmunotherapy, which may conflict with eligibility

**? Uncertainties:**
- No details on recent lab values including hemoglobin, ANC, platelet count, and liver function tests
- No clear indication if the patient has an extracranial lesion â‰¥ 3 cm amenable to grid therapy

**Assessment:**
> The patient's cancer type and stage match the trial's requirements. However, it is unclear if she qualifies based on progressing on osimertinib as her current treatment, as the trial looks for patients progressing on standard first-line immunotherapy or chemoimmunotherapy. Additionally, there are uncertainties regarding her most recent lab results and the size of metastases if any exist.

---

### [NCT06975293](https://clinicaltrials.gov/study/NCT06975293)

**Open-label, Non-randomized, Multi-cohort, Phase 1b/2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of STC-15 (a METTL3 Inhibitor) as a Part of Combination Therapy With Toripalimab in Participants With Selected Advanced Cancers**

- **Sponsor**: STORM Therapeutics LTD
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 65%

**âœ“ Supporting Factors:**
- Age: 52
- ECOG status: 0
- Cancer type: NSCLC
- Biomarkers: EGFR exon 19 deletion
- No brain metastases

**âœ— Potential Conflicts:**
- Prior therapies: osimertinib. The trial requires progression on prior anti-PD-1/L1 therapy, which the patient has not received.

**? Uncertainties:**
- Patient's eligibility based on having received anti-PD-1 therapy.
- Documented radiologic assessment of progression on the prior therapy before study entry is unspecified.
- Measurable disease according to RECIST v1.1 is unspecified.

**Assessment:**
> The patient's cancer type (NSCLC) matches the trial's indication. However, they have not received an anti-PD-1/L1 therapy, which is a requirement for eligibility, leading to uncertainties regarding eligibility based on treatment line criteria.

---

### [NCT05501665](https://clinicaltrials.gov/study/NCT05501665)

**SiCARIO (Split Course Adaptive Radioimmunotherapy) for the Treatment of Oligometastatic Non-Small Cell Lung Cancer (NSCLC) Using Biologically-Adaptive Radiotherapy - A Phase I/II Study**

- **Sponsor**: Vanderbilt-Ingram Cancer Center
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 50%

**âœ“ Supporting Factors:**
- Age: 52
- ECOG status: 0
- Cancer type: NSCLC is consistent with trial conditions studied
- Biomarker: PD-L1 TPS is 5% which meets the requirement for assessment but does not qualify for any threshold
- No brain metastases

**âœ— Potential Conflicts:**
- Prior therapies: patient has previously received osimertinib which may conflict with the treatment line requirement depending on the interpretation of trial descriptions

**? Uncertainties:**
- Assessment of required organ function (labs all WNL not explicitly stated)
- Patientâ€™s eligibility for immunotherapy-based systemic regimens is not explicitly stated
- Geographic bio-markers for eligibility are not provided; patient is located in the United States

**Assessment:**
> The patient has a diagnosis of NSCLC, which matches the trial conditions, but has previously been treated, and it's unclear whether treatment line criteria align with the trial's requirements. This introduces significant uncertainty, affecting confidence in eligibility.

---

## Excluded (43 trials)

### Excluded by Fast Filter

| NCT ID | Reason |
|--------|--------|
| [NCT07220096](https://clinicaltrials.gov/study/NCT07220096) | Patient age 52 is above maximum age 50 |
| [NCT02143830](https://clinicaltrials.gov/study/NCT02143830) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05058651](https://clinicaltrials.gov/study/NCT05058651) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05684965](https://clinicaltrials.gov/study/NCT05684965) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05785741](https://clinicaltrials.gov/study/NCT05785741) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06730750](https://clinicaltrials.gov/study/NCT06730750) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT07023731](https://clinicaltrials.gov/study/NCT07023731) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT03420963](https://clinicaltrials.gov/study/NCT03420963) | Patient age 52 is above maximum age 40 |
| [NCT04423029](https://clinicaltrials.gov/study/NCT04423029) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06475807](https://clinicaltrials.gov/study/NCT06475807) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06555744](https://clinicaltrials.gov/study/NCT06555744) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |

### Excluded by Eligibility Assessment

| NCT ID | Sponsor | Reason |
|--------|---------|--------|
| [NCT06262321](https://clinicaltrials.gov/study/NCT06262321) | University of Roches | Patient has targetable EGFR mutation (exon 19 deletion), while the trial requires non-targetable NSCLC. |
| [NCT04165070](https://clinicaltrials.gov/study/NCT04165070) | Merck Sharp & Dohme  | Patient has received prior systemic treatment (osimertinib) for metastatic NSCLC while the trial specifically includes only treatment-naive participants. |
| [NCT04181060](https://clinicaltrials.gov/study/NCT04181060) | National Cancer Inst | Patient has received prior treatment with osimertinib, which is an EGFR TKI, but this trial excludes prior anti-VEGF treatment, meaning the patient is not eligible to be treated under this study as specified in the eligibility criteria. |
| [NCT05671510](https://clinicaltrials.gov/study/NCT05671510) | OncoC4, Inc. | Patient has documented actionable mutations in EGFR, which is excluded by the trial criteria. |
| [NCT06452277](https://clinicaltrials.gov/study/NCT06452277) | Bayer | Patient has non-small cell lung cancer (NSCLC) with EGFR mutation, while trial is for patients with HER2-activating mutations. |
| [NCT06644768](https://clinicaltrials.gov/study/NCT06644768) | Daiichi Sankyo | Key inclusion criterion states: 'Has no prior systemic therapy for advanced or metastatic disease.' - Patient has received osimertinib. |
| [NCT00897117](https://clinicaltrials.gov/study/NCT00897117) | Vanderbilt-Ingram Ca | Patient has received prior systemic therapy (osimertinib) but trial excludes patients treated with chemotherapy before surgery. |
| [NCT05415358](https://clinicaltrials.gov/study/NCT05415358) | Wake Forest Universi | Patient has received prior therapy (osimertinib) but trial requires patients who have completed first line immune checkpoint inhibitor treatment. |
| [NCT05443126](https://clinicaltrials.gov/study/NCT05443126) | Ellipses Pharma | Patient has EGFR mutations (exon 19 deletion and C797S) which are major driver alterations other than RET as required by the trial. |
| [NCT05985655](https://clinicaltrials.gov/study/NCT05985655) | Exscientia AI Ltd.,  | Patient has progressed after prior osimertinib treatment which indicates they are not treatment-naive, while the trial criteria specify advanced solid tumors that are previously treated. |
| [NCT07223424](https://clinicaltrials.gov/study/NCT07223424) | Diwakar Davar | Patient is previously treated with osimertinib, trial requires treatment-naive patients. |
| [NCT07223047](https://clinicaltrials.gov/study/NCT07223047) | Bristol-Myers Squibb | Patient's cancer type is NSCLC; trial requires participants with a KRAS alteration but patient has EGFR mutation. |
| [NCT06150664](https://clinicaltrials.gov/study/NCT06150664) | Compass Therapeutics | Patient has not received 2 doses of PD-1/PD-L1 therapy, which is required for NSCLC eligibility. |
| [NCT06945484](https://clinicaltrials.gov/study/NCT06945484) | University of Utah | Patient is previously treated with osimertinib, which conflicts with the trial's requirement for neoadjuvant chemotherapy or immunotherapy and surgery. |
| [NCT03551951](https://clinicaltrials.gov/study/NCT03551951) | University of Missou | Patient has previously been treated with osimertinib; the trial appears to require treatment-naive patients. |
| [NCT05430009](https://clinicaltrials.gov/study/NCT05430009) | VA Ann Arbor Healthc | Patient has no liver metastases, while trial specifically studies patients with liver metastases. |
| [NCT06119581](https://clinicaltrials.gov/study/NCT06119581) | Eli Lilly and Compan | Patient has EGFR mutation (exon 19 deletion), while trial requires KRAS G12C mutation. |
| [NCT04155034](https://clinicaltrials.gov/study/NCT04155034) | SWOG Cancer Research | Patient has NSCLC, but trial is for small-cell lung cancer (SCLC). |
| [NCT05061550](https://clinicaltrials.gov/study/NCT05061550) | AstraZeneca | Patient has a sensitising EGFR mutation (exon 19 deletion) which excludes eligibility for this trial focused on resectable NSCLC without such mutations. |
| [NCT05715229](https://clinicaltrials.gov/study/NCT05715229) | Hackensack Meridian  | Patient has a prior treatment with osimertinib while the trial specifies that eligible patients will have newly diagnosed, previously untreated, histologically documented Stage IV NSCLC. |
| ... | ... | *and 12 more* |

## Search Terms Used

| Term | Source | Confidence |
|------|--------|------------|
| EGFR exon 19 deletion | manual | 1.0 |
| NSCLC | manual | 1.0 |
| EGFR exon 19 deletion NSCLC | manual | 1.0 |
| EGFR exon 19 deletion non-small cell lung cancer | llm | 0.9 |
| non-small cell lung cancer | llm | 0.8 |

## Information That Would Improve Matches

The following patient data was not provided but would help refine eligibility assessment:

- **Organ function labs** (hematology, liver, renal) - required by all interventional trials
- **Measurable disease status** (per RECIST 1.1) - required for most therapeutic trials
